Holzgrabe Ulrike, Muth Mathias
Universität Würzburg, Institut für Pharmazie und Lebensmittelchemie, Am Hubland, 97074 Würzburg.
Med Monatsschr Pharm. 2007 May;30(5):168-76; quiz 177-8.
COPD represents an underestimated and underdiagnosed disease with an enormous socioeconomic impact. Cigarette smoking is the main risk factor for the development of COPD. For this reason, prevention and smoking cessation form the mainstays of COPD therapy. During the last years, huge progress has been made in the understanding of the underlying pathophysiological processes and in the development of new therapeutic interventions that are different from that used in Asthma bronchiale. Long acting bronchodilators are the basis of COPD maintenance treatment. Besides the improvement in lung function they reduce dyspnoea and improve exercise tolerance and quality of life. However, in addition to pharmacological therapy intensive pharmaceutical care is crucial for COPD patients. Thus, pharmacists can contribute significantly to a successful management of the widespread disease COPD.
慢性阻塞性肺疾病（COPD）是一种被低估且诊断不足的疾病，具有巨大的社会经济影响。吸烟是COPD发病的主要危险因素。因此，预防和戒烟是COPD治疗的主要支柱。在过去几年中，我们对潜在病理生理过程的理解以及与支气管哮喘不同的新治疗干预措施的开发取得了巨大进展。长效支气管扩张剂是COPD维持治疗的基础。除了改善肺功能外，它们还能减轻呼吸困难，提高运动耐量和生活质量。然而，除了药物治疗外，强化药学监护对COPD患者至关重要。因此，药剂师可以为成功管理广泛存在的COPD疾病做出重大贡献。
